| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.2 | 1.1 |
| Profit before tax | -4.9 | -6.7 |
| Net income | -4.9 | -6.7 |
| EPS (diluted, $ a share) | $-0.04 | $-0.52 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +9.0% |
|---|---|
| Operating margin | -405.9% |
10-Q filed with the SEC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ionetix Corp: key numbers
- Shares outstanding
- 106.53MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ionetix Corp
All →Ionetix Stock Plan Amendment
Ionetix Corporation granted stock options to its CEO Kevin Cameron (1,025,600 shares) and CFO Phieu Phun (854,700 shares) under the 2026 Equity Incentive Plan. The options have an exercise price of $3.00 per share and follow a four-year vesting schedule. Additionally, the company adopted a new Non-Employee Director Compensation Plan governing equity awards for board members.
- Term
- 10 years